Faculty Spotlight: Gordon Gribble by Reed, Samuel R.
Dartmouth Undergraduate Journal of Science
Volume 19
Number 3 Influence: Science in Service to Society Article 1
2017
Faculty Spotlight: Gordon Gribble
Samuel R. Reed
Dartmouth, Samuel.R.Reed.19@Dartmouth.edu
Follow this and additional works at: https://digitalcommons.dartmouth.edu/dujs
Part of the Chemistry Commons
This Faculty Spotlight is brought to you for free and open access by the Student-led Journals and Magazines at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Undergraduate Journal of Science by an authorized editor of Dartmouth Digital Commons. For more
information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Reed, Samuel R. (2017) "Faculty Spotlight: Gordon Gribble," Dartmouth Undergraduate Journal of Science: Vol. 19 : No. 3 , Article 1.
Available at: https://digitalcommons.dartmouth.edu/dujs/vol19/iss3/1
SPRING 2017 3




Professor Gordon Gribble received his B.S. from U.C. Berkeley and his Ph.D. 
from the University of Oregon. He has been at Dartmouth for the past 49 years, 
and in that time he has taught chemistry to a great number of students. His 
research in the field of organic chemistry features indole and triterpenoid 
synthesis, and has yielded a wide range of medications.
BY SAM REED ‘19
FACULTY INTERVIEW
Figure 1: Dr. Gordon Gribble 
(right) is an esteemed Organic 
Chemistry Professor, role 
model, and mentor. This 
picture was taken at the 2002 
Goldschmidt Conference in 
Davos, Switzerland.
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diseases, but it’s really not sufficient to be used. So we had 
the idea, if you take one of these compounds – we chose two: 
oleanolic acid and ursolic acid. Chemically, we started to modify 
those compounds to see if we could amplify the biological 
activity. The 151st compound we synthesized, its called CDDO, 
was actually four thousand times more active than oleanolic acid, 
the starting materials. It’s a ten-step synthesis that took three 
years to accomplish, going from the stuff we get from olive oil to 
a compound that made it through phase three of clinical trials, 
after phase 1 and phase 2 trials for cancer and chronic kidney 
disease. 
So does a lot of your research still revolve around this 
triterpenoid, and if not, what does it consist of?
Right now I’m writing a new paper on a derivative of CDDO 
that we think will be better than the original CDDO, which is 
now called a bardoxolone methyl. We synthesized bardoxolone 
methyl in my laboratory in 1998, published it in 2000. We have 
a better synthesis reported a couple years ago, which actually 
reduces the number of synthetic steps in half. But the new 
compound, where we’ve made a compound having 1 less methyl 
group on what’s called the “A-ring,” has activity that’s about 10 
times better than bardoxolone methyl. So we’re very excited 
about that new compound.
But as you know, I’m retiring from teaching in August, and my 
research might go another two years or so but after that I’ll 
probably be out of the laboratory completely.
That’s a great bridge to my next question. Over the course 
of your career so far, what are the biggest ways your 
research has been impacted by your students?
Well Dartmouth students are incredibly intelligent, enthusiastic, 
and motivated, by-and-large. So that’s tremendous feedback that 
I receive when I work with undergraduates, and graduates, and 
post-docs as well. So that’s been a real joy with me; not only 
doing research with them but also teaching them. 
Any advice for a budding organic chemist?
Work a little bit all the time, keep on top of things, and if you’re 
into research as an undergraduate, you went to work with a 
professor and mentors in the laboratory. It’s a matter of dedication 
and falling in love with what you’re doing in the laboratory, as I 
did a long time ago. 
Why organic chemistry as opposed to a different field of 
chemistry?
It all goes back to 1951 when I was 10 years old. I got a chemistry 
set for Christmas and, I remember, I was working with my dad in 
the kitchen, doing experiments. I really loved the idea of making 
something new, noticing how chemicals react to form colors, 
smoke, things like that. In fact, I was making firecrackers and 
sparklers later on when I was maybe 12-14.
So you really budded early then?
I was very interested in chemistry. In those days you could 
actually go to a chemistry store and buy things like concentrated 
sulfuric acid. I remember my mother taking me to J.T. Baker 
Chemical Company in San Francisco and buying a concentrated 
bottle of sulfuric acid, which you could never do today, of course.
How do you think organic chemistry can advance fields 
of public health in ways that other fields of chemistry 
cannot?
Well organic chemistry, of course, is the chemistry of carbon 
compounds. All pharmaceuticals, all new drugs, almost all new 
materials, are based on carbon. Carbon is the central element in 
organic chemistry, of course.
I know that a lot of your work has to do with indoles. What 
can this work do for the field of chemistry? 
Well indol is a heterocyclic, two-ring system that is in everything 
we eat. It’s in tryptophan. It’s in serotonin - our brain chemical. 
It’s in pharmaceuticals, and has many biological applications. 
All migraine drugs, for example (and that’s just one example), 
contain the indole core, and indole is a ubiquitous compound, as 
I mentioned. It’s in lots of pharmaceuticals and materials. Nature 
uses the indole ring to make a myriad of natural products.
I’ll ask you the same question about triterpenoids.
Triterpenoids are in everything we eat also, although they 
don’t contain nitrogen. They’re biosynthesized from acetic acid, 
actually - which is something we eat – but they’re in things 
like cranberries, pokeberries, really all plant material contains 
some triterpenoids. Ursolic acid is a common one in cranberries. 
Oleanolic acid common in leaves to make our potential drug, is in 
olive oil, for example. And in rosemary, that’s another biological 
source.
When you’re beginning your research, do you think of a 
problem you want to solve and then devise a structure, or 
do you create a novel structure, and then see how it can 
be used?
A combination of that. With the triterpenoid that we invented 
in 1998, we started with the premise that triterpenoids in plants 
have some biological activity, some anti-inflammatory activity, 
some anti-cancer activity. Probably not sufficient enough to be 
used in the clinic, to be used as a drug. Folk medicine reports 
uses of things like oleanolic acid, ursolic acid, to treat various 
D
